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Abstract
Depressive symptoms may increase the risk of progressing from mild cognitive impairment (MCI) to dementia. Consumption of n-3 PUFA
may alleviate both cognitive decline and depression. The aim of the present study was to investigate the benefits of supplementing a diet
with n-3 PUFA, DHA and EPA, for depressive symptoms, quality of life (QOL) and cognition in elderly people with MCI. We conducted a
6-month double-blind, randomised controlled trial. A total of fifty people aged .65 years with MCI were allocated to receive a supplement
rich in EPA (1·67 g EPA þ 0·16 g DHA/d; n 17), DHA (1·55 g DHA þ 0·40 g EPA/d; n 18) or the n-6 PUFA linoleic acid (LA; 2·2 g/d; n 15).
Treatment allocation was by minimisation based on age, sex and depressive symptoms (Geriatric Depression Scale, GDS). Physiological
and cognitive assessments, questionnaires and fatty acid composition of erythrocytes were obtained at baseline and 6 months (completers:
n 40; EPA n 13, DHA n 16, LA n 11). Compared with the LA group, GDS scores improved in the EPA (P¼0·04) and DHA (P¼0·01) groups
and verbal fluency (Initial Letter Fluency) in the DHA group (P¼0·04). Improved GDS scores were correlated with increased DHA plus EPA
(r 0·39, P¼0·02). Improved self-reported physical health was associated with increased DHA. There were no treatment effects on other
cognitive or QOL parameters. Increased intakes of DHA and EPA benefited mental health in older people with MCI. Increasing n-3
PUFA intakes may reduce depressive symptoms and the risk of progressing to dementia. This needs to be investigated in larger, depressed
samples with MCI.
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Dementia, the most common form being Alzheimer’s disease,
is characterised by progressive and profound loss of memory,
cognitive function and ability to carry out daily functional
activities of living. It has been associated with various genetic
and environmental risk factors(1). Its prevalence is increasing
rapidly worldwide(2) and it represents a major public health
concern. Therefore, any delay in its onset will have significant
social and economic impacts, making early intervention an
international imperative. It has been suggested that mild
cognitive impairment (MCI) is possibly the earliest stage of
detectable dementia(3) and may be the optimal time to inter-
vene with preventive therapies(4). Furthermore, major and
minor depression often occurs in patients with MCI(5), and
this increases the risk of progressing to dementia(6).
In Western populations, there has been a marked decrease
in the dietary intake of n-3 PUFA along with a substantial
increase in the consumption of n-6 PUFA(7). The long-chain
n-3 PUFA DHA (22 : 6n-3) is highly concentrated in the brain
and has been associated with numerous structural and func-
tional roles(8–10). The long-chain n-3 PUFA EPA (22 : 5n-3) is
also thought to have important functions in the brain(11) via
the synthesis of benign eicosanoids that tend to counter
the inflammatory, thrombotic and primarily vasoconstrictor
properties of eicosanoids produced from the n-6 PUFA ara-
chidonic acid (AA; 20 : 4n-6)(12).
With ageing, neural membrane fluidity is compromised due
to the increased presence of cholesterol, the reduced activity
of desaturase enzymes, blockages to phospholipid pathways
*Corresponding author: Dr N. Sinn, fax þ61 8 302 2794, email natalie.sinn@unisa.edu.au
Abbreviations: AA, arachidonic acid; GDS, Geriatric Depression Scale; LA, linoleic acid; MCI, mild cognitive impairment; WAIS III, Wechsler Adult
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and increased oxidative stress(13), all of which are inversely
associated with PUFA. Brain autopsies of Alzheimer’s disease
patients have shown significantly higher saturated fat and
lower n-3 PUFA content in the hippocampus and frontal
lobes (governing memory and executive function, respect-
ively) compared with age-matched controls(14), consistent
with reports of decreased hippocampus size and function in
Alzheimer’s disease patients(13).
To date, few clinical trials evaluating the benefits of n-3
PUFA in patients with dementia have been published,
although more are under way(15). There are some reports
of benefit(16,17). However, larger trials indicate that people
with MCI are more likely to respond. These studies investi-
gated supplementation of n-3 PUFA in patients with dementia
but only found improvements in the subgroups with mild
cognitive decline(18–20). In elderly, cognitively healthy popu-
lations, there does not appear to be benefit(21,22); however,
a recent study did report improvements following DHA sup-
plementation in elderly people with age-related cognitive
decline(23). This body of studies supports indications that
intervention with n-3 PUFA may be more effective in early
stages of cognitive decline, yet no studies have yet focused
exclusively on people with MCI and therefore possibly in
the early stages of dementia onset.
Depression is very common in older adults with MCI and
increases the risk of developing dementia(6). Clinical trials
investigating the efficacy of n-3 supplementation in alleviating
depressive symptoms have found positive results in about half
of published studies(15,24). Among other methodological
differences, studies have used varying ratios of EPA:DHA;
some have used only DHA or ethyl-EPA.
The purpose of the present study was to compare the
effects of high-EPA and high-DHA fish oils with n-6 PUFA
linoleic acid (LA; 18 : 2n-6), a vegetable oil, on depressive
symptoms, quality of life, memory and executive function in
elderly people with MCI, to investigate the associations
between increased erythrocyte DHA and EPA levels and any
improved symptoms, and to determine whether those with
lower baseline erythrocyte PUFA levels respond more readily
to supplementation.
Experimental methods
Participants and procedure
Eligibility criteria considered discussions by the International
Working Group on MCI(3,25). Identification of MCI is gener-
ally defined as signs of cognitive decline beyond those
expected for age but not dementia. Therefore, subjective
complaints of memory loss but otherwise normal daily func-
tioning are recommended, along with cognitive assessment
scores $1·5 SD below the population mean. We screened
elderly people aged over 65 years who had self-reported
memory loss, were able to maintain normal daily functioning
and gave informed consent, did not eat fish more than
once per week, and had not taken any fish oil supplements
within the previous 3 months. They had to be prepared
to attend a screening, complete two rounds of assessments,
take daily supplements, keep a weekly diary of fish intake
and not to consume fish more than once per fortnight
during the study. Those who met the following criteria
after screening were invited to take part: standardised
Mini-Mental State Examination scores $22 (a score #20
indicates possible dementia), recall memory (Verbal Paired
Associates Task(26)) age-standardised scores $1·5 SD below
the population mean and/or age- and education-adjusted
DemTect scores between 9 and 12(27) (these tests are des-
cribed further below).
According to Cohen’s f, the required n to detect a medium
effect size (d ¼ 0·50) in a repeated-measures within–between
interaction design for three groups with a power of 0·80 is
sixty-six participants (twenty-two per group). Recruitment
took place in Adelaide and Brisbane, Australia, via news-
paper, magazine and radio advertisements, retirement villages
(talks and letterbox drops), Alzheimer’s Association, shop-
ping malls and television. A flow chart of participants
through the study is depicted in Fig. 1. After 6 months of
extensive screening, fifty eligible volunteers were recruited:
forty-four in Adelaide and six in Brisbane (see Table 1 for
baseline characteristics), of whom forty completed the
6-month assessments. This provided adequate power to
detect an effect size of d ¼ 0·64, or d ¼ 0·56 with all cases
(n 50) included in the analyses (assuming a balanced
dataset). The intervention took place between March 2009
and March 2010.
As participants were enrolled, they were independently
allocated to one of three conditions (EPA-rich oil, DHA-
rich oil or placebo) using the process of minimisation
based on age, Geriatric Depression Scale (GDS) scores and
sex, respectively. Altman & Bland(28) recommended this
simple process for small trials with progressive enrolment
in order to achieve balanced treatment groups without
investigator bias. Of the participants, eighteen (36 %) had
GDS scores of 4 or above, indicating possible depression.
All researchers involved with participants, data entry or anal-
ysis and participants were blinded to treatment conditions.
Supplements were coded and labelled independently; parti-
cipants were asked at 6 months which condition they
thought they were in (and why) and these observations
were recorded.
Eligible volunteers completed assessments at baseline and
6 months at the University of South Australia (Adelaide,
SA, Australia) or the Institute of Health and Biomedical
Innovation (Brisbane, QLD, Australia) in the morning follow-
ing an overnight fast. Height, weight and blood pressure
were measured and blood samples collected. Volunteers
were then offered breakfast (toast, cereal, tea, orange juice
and water) and underwent 45 min of cognitive assessments.
The same instructions and protocol were used for each
volunteer’s assessments.
The project was performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki,
and all procedures involving human participants were
approved by the Human Research Ethics Committees at
the University of South Australia and Queensland University
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of Technology. Informed written consent was obtained from
all participants.
Supplements
Participants were randomly allocated to EPA-rich fish oil, pro-
viding 1·67 g EPA þ 0·16 g DHA/d, DHA-rich fish oil, provid-
ing 1·55 g DHA þ 0·40 g EPA/d, or control (safflower oil),
providing 2·2 g LA (n-6 PUFA)/d for 6 months. The oils were
taken in four capsules daily. Participants were asked to
return all of their jars at the end of the study and capsules
were counted to assess compliance. Adverse events were
recorded on the 6-month questionnaires and via regular
phone calls throughout the study.
Assessment tools
All of the following assessments were conducted at baseline
and 6 months.
Depression and quality of life
Geriatric depression scale. The fifteen-item short form of the
GDS(29) was our primary outcome measure of depressive
symptoms. Respondents circle ‘yes’ or ‘no’ in response to a
series of statements, e.g. ‘Are you in good spirits most of the
time’, ‘Do you feel that your life is empty’. A score of one
point is allocated for each response that is indicative of poss-
ible depression. Therefore, a higher score indicates greater
symptom severity; scores of 4 or above possible depression.
The highest possible score is 15.
Expressed interest n 328
(n 293 UniSA, n 35 QUT)
Turned up for MCI screening n 118
(n 88 UniSA, n 30 QUT) 
Initial screening by phone or in person
n 291 (n 256 UniSA, n 35 QUT)
Unable to contact those who had
left messages (n 37 UniSA) 
Invited to take part and block-
randomised to treatment n 54
(n 47 UniSA, n 7 QUT)
Invited for MCI screening
(n 111 UniSA, n 30 QUT)
LA placebo (n 18) DHA-rich oil (n 18) EPA-rich oil (n 18)
Completed baseline
assessments (n 15)
Completed baseline
assessments (n 18)
Completed baseline
assessments (n 17)
Completed 6-month
assessments (n 11) 
Loose bowels (n 2)
Dementia (n 1)
Pancreatitis operation
(n 1)
Completed 6-month
assessments (n 16)
Moved states (n 1)
Operation (n 1)
Completed 6-month
assessments (n 13)
Diverticulitis (n 1)
Dizzy spells (n 1)
Changed mind (n 1)
Lost to follow-up (n 1)
Fig. 1. Flow of participants through the study. UniSA, University of South Australia; QUT, Queensland University of Technology; MCI, mild cognitive impairment;
LA, linoleic acid.
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SF-36 health survey. This survey assesses eight domains
of health and quality of life: physical functioning, limitations
in usual role due to physical health problems (role – physi-
cal), bodily pain, general health, vitality, social functioning,
limitations in usual role due to emotional problems (role –
emotional) and mental health. By combining these domains,
two further subscales are derived: physical health and
mental health. We used the Australian adaptation(30). Where
necessary, scales are reverse-scored so that on all the scales,
a higher score indicates better health. Each subscale varies
in the length of items; each item response is given from a
selection varying from ‘excellent’ to ‘poor’, ‘yes, limited a lot’
to ‘no, not limited at all’, ‘all of the time’ to ‘none of the
time’, and so on, depending on the nature of the question.
Cognition. Subjective and objective tests were selected
that can predict memory loss or dementia and may therefore
be sensitive to meaningful improvements in or alleviations
of cognitive decline. We selected specific subtests that may
be sensitive to the effects of the intervention on memory
and executive function and have been used previously in
drug trials for MCI(31). Where necessary, alternate versions of
the tests were used for re-test purposes.
Table 1. Baseline sample characteristics (n 50)*
(Mean values, standard deviations, number of participants and percentages)
Control (LA, n 15) DHA-rich oil (n 18) EPA-rich oil (n 17)
Mean SD Mean SD Mean SD
Age (years) 73 3·96 74·22 7·00 74·88 5·06
Sex (male)
n 7 13 14
% 47 72 82
Highest level of education attained† 3·14 1·88 2·56 1·98 2·67 1·50
Family history of dementia or AD
n 5 3 6
% 33 17 35
Baseline MMSE score 27·73 2·22 27·83 1·92 25·94 3·31
Baseline VPA score 6·87 3·07 6·22 2·53 6·31 2·12
Baseline DemTect score 13·87 3·16 13·22 3·41 12·18 2·63
Baseline GDS score 3·15 2·08 3·19 3·17 4·40 2·92
BMI (kg/m2) 28·11 5·27 26·80 2·58 28·05 4·07
Systolic blood pressure (mmHg) 131·13 18·51 136·52 20·07 139·02 19·69
Diastolic blood pressure (mmHg) 76·33 10·46 79·83 9·91 80·10 9·49
Resting heart rate (bpm) 55·33 10·96 64·08 12·54 58·93 8·14
Diabetes
n 2 4 1
% 13 22 6
Current smoker‡
n 0 0 2
% 0 0 12
Excess alcohol§ 2·33 1·18 2·22 1·22 2·38 1·41
SF-36 physical functioning 23·71 4·88 24·94 3·80 24·00 4·83
SF-36 vitality 15·60 3·23 17·29 3·00 16·44 3·74
SF-36 bodily pain 8·00 1·73 8·29 1·99 8·41 2·40
SF-36 physical health 63·82 11·62 66·81 9·91 67·15 11·20
SF-36 role – physical 14·40 4·58 15·50 2·73 14·75 3·98
SF-36 role – emotional 11·29 3·100 11·06 2·22 11·00 3·08
SF-36 mental health 58·79 10·81 24·53 3·68 58·94 11·69
RAVLT, total immediate recall 37·43 6·93 34·78 9·00 30·41 8·51
RAVLT, immediate delayed recall 6·00 3·23 5·89 2·95 4·94 3·03
RAVLT, 20 min delayed recall 9·79 3·02 5·39 3·81 8·76 3·29
Digits Forward score 9·60 1·84 9·28 1·99 9·88 2·12
Boston Naming Task 51·53 6·32 53·94 6·77 51·47 5·52
Letter-Number Sequencing 8·40 2·03 7·00 2·61 6·53 2·48
Digits Backward score 5·87 1·60 6·06 1·39 5·35 1·41
Trail-Making score 3·00 1·27 3·34 1·28 3·43 1·50
Stroop Colour-Word Test score 2·94 0·70 3·06 0·78 3·20 1·17
Initial Letter Fluency total 23·60 8·18 21·39 7·14 18·24 8·45
Excluded Letter Fluency total 15·67 6·43 14·50 6·84 11·59 4·45
LA, linoleic acid; AD, Alzheimer’s disease; MMSE, Mini-Mental State Examination; VPA, Verbal Paired Associates (age- and
sex-adjusted standardised score, M ¼ 10); GDS, Geriatric Depression Scale (scores .4 may indicate clinical depression);
bpm, beats per minute; RAVLT, Rey Auditory Verbal Learning Test
* Mean values were not significantly different between the groups for any of these variables (one-way ANOVA or x 2 tests).
† Education: 1, years 8–10; 2, year 11; 3, year 12; 4, technical and further education (or 13–14 years of total education);
5, university; 6, postgraduate.
‡ Current smoker: ‘yes/no’.
§ Frequency of consuming more than two alcoholic drinks per d (1, never/rarely; 2, occasionally; 3, once per week; 4, few days
per week; 5, daily). The SF-36 scales are reverse-scored, where necessary, so that a higher score always represents improved
health; each scale has a different scale and number of items and therefore different possible total scores.
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Memory
Memory Functioning Questionnaire. This questionnaire(32)
assesses four domains of subjective perception of memory
loss in the recent and more distant past: general frequency
of forgetting, seriousness of forgetting, retrospective function-
ing and mnemonics usage.
Rey Auditory Verbal Learning Test. This test(33) measures
immediate, delayed recall and recognition memory(32). It
requires participants to recall a list of fifteen words learned
over five trials, immediately, then after a distracter list and
again 20 min later. To test recognition memory, they are
then given a list of words containing the target words and
asked to select those that were on the list. The immediate
memory score is calculated by adding trials 1–5 together
(total 75), the delayed recall by totalling the number of
words recalled on that trial (total 15) and recognition
memory by totalling the number of words correctly recognised
(total 15).
Digits Forward. It is a subtest from the Wechsler Adult
Intelligence Scale (WAIS III)(34) that requires participants
to recall a random series of numbers starting with 2 and
increasing to 9. The task is discontinued following failure on
both items of the same length. The maximum score that can
be obtained is 16 (two on each trial).
Boston Naming Task. This task(33) tests verbal expression
and may predict dementia(35). It consists of sixty large pictures
of items ranging in familiarity from common items such
as ‘pencil’ to less common objects such as ‘sphinx’ and is
discontinued after eight consecutive failures. A score of one
point is given for each correct response; the maximum score
that can be obtained is 60.
Executive function/working memory
Letter-Number Sequencing. It is a subtest of the WAIS III(33)
that measures working memory and executive function. It
requires participants to recall strings of digits and letters, reor-
ganising them so that digits are recalled first in numerical
order and then letters in alphabetical order, starting with
two and increasing up to eight consecutive letters/numbers
with two trials of each. It is discontinued following failure
on both items of the same length. The maximum score that
can be obtained is 14 (two on each trial).
Digits Backward. It is another subtest from the WAIS III
that measures working memory and executive function(34).
Following Digits Forward, participants are asked to recall
number sequences in reverse order, starting with two and
increasing to eight numbers and discontinued following
failure on both items of each trial. The maximum score that
can be obtained is 14 (two on each trial).
Trail-Making Task. This task(33) is a measure of scanning
and visuomotor tracking, divided attention, and cognitive
flexibility. It requires volunteers to draw lines as quickly as
they can to connect consecutively numbered circles on one
worksheet (part A) and then connect consecutively numbered
and lettered circles on another worksheet by alternating
between the two sequences (part B). The score is derived
by dividing the time taken (in s) during part B by the time
taken during part A.
Stroop Colour-Word Test. This test(36) measures the ability
to ignore distracting information. Part A requires participants
to read a sheet of colour names. In part B, they are asked to
name the colours (which are incongruent with the words;
for example, the word blue may be printed in the colour
red) and ignore the words. The score is derived by dividing
the time taken (in s) during part B by the time taken during
part A.
Verbal fluency. Strategic retrieval of verbal material was
assessed by tests of initial and excluded letter fluency(37,38).
These tests require participants to produce as many words
as possible within 60 s either beginning with a designated
letter (e.g. F, S) or not containing a designated letter
(e.g. E, A), respectively. A score of one point is given for
each correct word that is generated within 60 s for each
respective trial.
Potential confounders. A background questionnaire
assessed potential confounders: highest level of education,
frequency of consuming more than two alcoholic drinks/d,
whether or not they smoke, medications, medical conditions
and family history of dementia (see Table 1).
Physiological parameters. We tested heart rate, BMI and
blood pressure as potential confounders. Height and weight
were measured by a stadiometer (Seca, Hamburg, Germany)
and scales (Tanita, Tokyo, Japan), respectively. Blood samples
were collected into 6 ml K3EDTA tubes, 5 ml serum tubes
and 4 ml lithium heparin tubes (Interpath Services Pty Ltd,
Heidelberg West, VIC, Australia) by venepuncture. Following
the blood sample, volunteers were invited to rest quietly in
a darkened room for a minimum of 10 min before three
measures of blood pressure and heart rate were taken using
an automatic blood pressure monitor (model IA1B; Omron,
Kyto, Japan), with 5 min rest between each measure.
Assessment of fatty acid profiles. Relative proportions of
individual fatty acids in erythrocytes were assessed using a
method adapted from previously established methods(39–41).
Erythrocytes were isolated within 2 h of collection by cen-
trifugation, washed in isotonic saline and stored at 2808C.
They were subsequently thawed and the lipids were
extracted with chloroform and isopropanol (2:1). The
organic phase containing the lipid was evaporated to
dryness under a stream of N2 gas. The lipids were then
transesterified with acetyl chloride in methanol toluene
(4:1, v/v) at 1008C for 1 h. The resultant fatty acid methyl
esters were extracted with 10 % potassium carbonate. Fatty
acid methyl esters were separated and quantified using a
Shimadzu 2010 gas chromatograph equipped with a 50 m
capillary column (0·32 mm, inner diameter) coated with
BPX-70 (0·25mm film thickness; SGE Analytical Science Pty
Limited, Ringwood, VIC, Australia). The injector temperature
was set at 2508C and the detector (flame ionisation) tem-
perature at 2608C. The initial oven temperature was 1308C
and was programmed to rise to 2208C at 58C/min. H2 was
used as the carrier gas at a velocity of 36·4 cm/s. Fatty
acid methyl esters were identified based on the retention
time to authentic lipid standards (GLC-463; Nu-Chek Prep,
Inc., Elysian, MN, USA).
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Statistical analysis
Data analysis was conducted using SPSS Statistics (version
17.0; SPSS, Inc., Chicago, IL, USA). Baseline one-way
ANOVA were used for parametric data and x 2 analyses for
non-parametric data to examine whether demographic,
physiological and dependent variables (mood, quality of
life and cognition) were evenly distributed between the
groups. Linear mixed model analyses were planned to inves-
tigate the effects of DHA and EPA v. LA on outcome variables
(assuming data were missing at random). Regressions were
used to investigate the correlations between increased PUFA
levels and improved outcomes and baseline PUFA levels
with improved outcomes. Due to the relatively small sample
size, P values were set at 0·05 to avoid the possibility of a
type II error.
Results
Adverse events
The treatments were well tolerated apart from a few gastro-
intestinal-related complaints. From the LA (control) group,
three complained of bowel problems, one of nausea and
one had reflux. From the EPA-rich oil group, there was one
case reported for each of the following: flatulence, nausea,
reflux and upset stomach, and one participant withdrew due
to diverticulitis. No adverse events were reported in the
DHA group.
In the LA, DHA and EPA groups, one, eight and six persons,
respectively, guessed that they had been taking fish oil
(P¼0·09); six, three and two individuals, respectively, guessed
they were on placebo and two, five and three did not know.
However, of the people who guessed the condition they were
in, whether correctly or not, one, three and five from each
group said it was because of a fishy taste; seven, seven and
three said it was because they thought they were either not
deriving or were deriving benefits (mostly physical, e.g. less
aches and pains) from the treatment. Therefore, treatment
blinding was successful on the whole.
Compliance
Capsule counts indicated excellent compliance, with an aver-
age supplement consumption of 93 % across the groups
(DHA 97 %, EPA 94 % and LA 82 %). This is confirmed
by changes in erythrocyte n-3 and n-6 PUFA levels after
6 months for each treatment group (see Table 2). As shown
in Table 2, PUFA levels corresponded to the respective treat-
ments (e.g. DHA levels increased in the DHA treatment
group, etc.).
Primary analysis: effect of the supplement
There were eleven missing observations in the follow-up
data; however, demographic data were complete. Logistic
regression, with missingness as the dependent variable and
demographic variables (sex, age, condition, history of
dementia and Alzheimer’s disease) as predictors, showed
that none of the predictors were significant in predicting
missingness, and the number of dropouts between the
Table 2. Erythrocyte PUFA levels at baseline and 6 months in each treatment group (as percentage
of fatty acids)*
(Mean values and standard deviations)
Baseline 6 months
Change in
P value†Mean SD Mean SD
LA control group (n 15, n 11)
EPA 0·95 0·37 0·79 0·17 0·127
DHA 4·74 1·00 4·58 1·13 0·096
Total n-3 PUFA 8·40 1·55 8·16 1·43 0·270
LA 8·20 1·61 7·24 0·88 0·072
AA 11·39 1·17 12·08 0·77 0·171
Total n-6 PUFA 24·19 1·65 24·38 1·40 0·886
DHA group (n 18, n 16)
EPA 0·97 0·25 1·83 0·38 0·000
DHA 4·55 0·68 8·65 0·83 0·000
Total n-3 PUFA 8·21 1·03 12·85 1·27 0·000
LA 7·80 1·24 6·00 0·61 0·000
AA 11·64 1·48 10·22 1·52 0·000
Total n-6 PUFA 24·07 1·27 19·69 1·37 0·000
EPA group (n 17, n 12)
EPA 0·96 0·23 4·06 0·76 0·000
DHA 4·56 0·81 5·34 0·65 0·002
Total n-3 PUFA 8·31 1·00 14·35 1·56 0·000
LA 7·80 (1·36) 5·66 (0·97) 0·000
AA 11·53 (0·91) 9·49 (0·96) 0·000
Total n-6 PUFA 23·91 (1·37) 18·14 (1·19) 0·000
LA, linoleic acid; AA, arachidonic acid.
* Mean values were not significantly different between the groups for baseline PUFA levels (one-way ANOVA).
† Changes from baseline to 6 months were analysed using paired-samples t tests.
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Table 3. Treatment effects (time £ treatment interactions) for linear mixed model analysis of all cases as
randomised to treatment (EPA v. linoleic acid (LA), DHA v. LA) on depression, health-related quality of life and
cognitive assessments over 6 months (n 50; LA n 15, DHA n 18, EPA n 17)
(Estimates, standard errors and 95 % confidence intervals)
Estimate SE t score P 95 % CI ICC†‡
Depression and quality of life
Geriatric depression scale† 0·87
EPA v. LA 21·23 0·56 22·18 0·04* 22·37, 20·09
DHA v. LA 21·40 0·53 22·62 0·01* 22·47, 20·32
SF-36 physical functioning 0·82
EPA v. LA 20·02 1·12 20·02 0·98 22·30, 2·25
DHA v. LA 1·30 1·05 1·23 0·23 20·84, 3·43
SF-36 vitality 0·73
EPA v. LA 0·73 1·01 0·72 0·47 21·32, 2·79
DHA v. LA 1·57 0·94 1·68 0·10 20·33, 3·47
SF-36 bodily pain 0·52
EPA v. LA 0·19 0·85 0·22 0·83 21·53, 1·91
DHA v. LA 0·83 0·81 1·03 0·31 20·80, 2·47
SF-36 physical health 0·77
EPA v. LA 21·44 3·12 20·46 0·65 27·78, 4·90
DHA v. LA 3·73 2·86 1·31 0·20 22·07, 9·54
SF-36 role – physical 0·57
EPA v. LA 0·09 1·36 0·07 0·95 22·66, 2·85
DHA v. LA 0·74 1·30 0·57 0·57 21·89, 3·38
SF-36 role – emotional 0·67
EPA v. LA 0·10 1·00 0·10 0·92 21·92, 2·13
DHA v. LA 0·31 0·93 0·34 0·74 21·57, 2·20
SF-36 mental health 0·77
EPA v. LA 5·43 3·09 1·76 0·09 20·83, 11·69
DHA v. LA 3·29 2·73 1·20 0·24 22·26, 8·83
Cognitive assessments
RAVLT, total 0·56
EPA v. LA 20·75 3·16 20·24 0·81 27·14, 5·65
DHA v. LA 22·28 3·00 20·76 0·45 28·35, 3·79
RAVLT, delayed recall 0·79
EPA v. LA 0·53 0·93 0·57 0·57 21·35, 2·42
DHA v. LA 0·36 0·88 0·41 0·69 21·43, 2·14
RAVLT, recognition 0·51
EPA v. LA 0·56 1·38 0·41 0·69 22·23, 3·35
DHA v. LA 0·02 1·31 0·02 0·99 22·63, 2·67
Digits Forward 0·50
EPA v. LA 20·62 0·84 20·74 0·47 22·32, 1·08
DHA v. LA 0·12 0·80 0·15 0·88 21·49, 1·73
Boston Naming Task 0·80
EPA v. LA 21·68 1·34 21·25 0·22 24·41, 1·05
DHA v. LA 21·56 1·24 21·26 0·22 24·07, 0·96
Letter-Number Sequencing 0·36
EPA v. LA 0·22 0·81 0·27 0·79 21·43, 1·87
DHA v. LA 0·12 0·77 0·15 0·88 21·44, 1·68
Digits Backward 0·43
EPA v. LA 20·74 0·75 20·99 0·33 22·24, 0·77
DHA v. LA 21·20 0·71 21·69 0·10 22·63, 0·23
Trail-Making Task 0·32
EPA v. LA 0·14 0·64 0·22 0·83 21·15, 1·43
DHA v. LA 0·42 0·59 0·71 0·48 20·77, 1·61
Stroop score 0·53
EPA v. LA 20·42 0·39 21·08 0·29 21·21, 0·37
DHA v. LA 20·37 0·37 21·00 0·32 21·13, 0·38
Initial letter fluency 0·76
EPA v. LA 1·07 2·12 0·51 0·62 23·22, 5·37
DHA v. LA 4·16 1·99 2·09 0·04* 0·12, 8·21
Excluded letter fluency 0·51
EPA v. LA 22·26 2·44 20·93 0·36 27·19, 2·66
DHA v. LA 20·56 2·31 20·24 0·81 25·23, 4·11
ICC, intra-class correlations; RAVLT, Rey Auditory Verbal Learning Test.
* Values were significantly different (P,0·05).
† Geriatric Depression Scale results shown with a statistical outlier removed from the placebo group.
‡ ICC gives the percentage of variance explained by individual subject differences; over 50 % indicates reasonable goodness of fit.
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groups was not significantly different (P¼0·39). Therefore,
it was reasonable to assume that the data were missing
at random at worst. The application of a linear multilevel
model was appropriate for this missing pattern. All infor-
mation could be used and predicted values could be
obtained for all participants at each time point(42). However,
for the Memory Functioning Questionnaire, there were only
twelve cases without missing data. Data imputation resulted
in unacceptable data variability, so the Memory Functioning
Questionnaire was not included in the analyses. Baseline
comparisons between the groups showed no significant
differences between the groups for outcome variables (data
not shown). Treatment effects on outcome variables were
assessed via visit (baseline and 6 months) £ treatment inter-
actions for the DHA and EPA groups compared with the LA
group using linear mixed model analysis (Table 3).
Depressive symptoms
Following inspection of data distributions, one statistical
outlier was removed from the placebo group in Brisbane as
the GDS change score was .3 SD from the mean(43) (nine at
baseline and three at 6 months). According to Osborne &
Overbay(44), ‘the presence of outliers can lead to inflated
error rates and substantial distortions of parameter and statistic
estimates when using either parametric or nonparametric
tests’. Following the removal of this outlier, there was a signifi-
cant improvement in depression (GDS) scores in the EPA
(P¼0·04) and DHA (P¼0·01) groups compared with the LA
group (Fig. 2; Table 3). The amount of variance explained
was 87 %, indicating a very good fit of the model to the
data. The magnitude of change was slightly less than 0·5 SD
in the EPA group and greater than 0·5 SD in the DHA
group, which is accepted as a meaningful improvement in
health-related quality of life(45). Paired-samples t tests found
that within-group changes within each condition were only
significant in the DHA group (P¼0·02).
Quality of life
There were no significant treatment effects on outcomes
using mixed model analysis for physical or mental quality of
life parameters (Table 3).
Memory and cognitive function
From assessments of memory and cognitive function,
only Initial Letter Fluency scores significantly improved
in the DHA treatment group compared with the LA
group (P¼0·04), explaining 76 % of the variance and there-
fore a very acceptable goodness of fit (Fig. 3; Table 3).
The Digits Backward score also showed improvement in
the DHA group, although not statistically significant
(P¼0·10). The intra-class correlations in Table 3 indicate
that the majority of outcome variables showed an acceptable
fit of the data to the model and yet no other treatment
effects.
Associations between increased erythrocyte PUFA and
changes in outcome variables
Table 4 shows correlations between increased erythrocyte
PUFA levels and improvements in outcome variables.
Increased DHA plus EPA was correlated with improved
depressive symptoms on the GDS (P¼0·02). A reduced
AA:EPA ratio was also associated with reduced depressive
symptoms, further supporting the mixed model analysis
results. Similarly, increased AA was associated with declines
in self-reported mental health and a reduced AA:EPA ratio
was correlated with improved self-reported mental health
and vitality.
Increased DHA was significantly associated with improved
self-reported physical functioning on the SF-36, and of those
subscales, improved bodily pain was associated with
improved depressive symptoms (P,0·05); therefore, this
may to some degree have contributed to improved mood.
Baseline erythrocyte PUFA levels and improved outcome
measures
There were no significant correlations between baseline
erythrocyte PUFA levels and improved outcome measures.
However, comparisons between those with EPA plus DHA
levels below and above the 50th percentile indicate that
those with lower levels tended to show greater improvement
in GDS scores (P¼0·066), physical functioning (P¼0·069),
physical health (P¼0·088) and bodily pain (P¼0·058).
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Fig. 3. Comparison of changes in Initial Letter Fluency: DHA significantly
different from linoleic acid (LA; P¼0·04).
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Fig. 2. Comparison of changes in depression scores in the treatment groups:
DHA and EPA significantly different from linoleic acid (LA; P¼0·01, P¼0·03,
respectively). Values are means, with standard deviations represented by
vertical bars.
EPA, DHA, mood and cognition in elderly people 1689
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
Table 4. Correlations between change in PUFA and outcome variables from baseline to 6 months†
EPA DHA E þ D AA n-6 A:E GDS RAV Rcl Rec BNT Strp ILF ELF LNS TM DF DB PF PH MH BP Vit
EPA 1·00
DHA 20·05 1·00
E þ D 0·54** 0·81** 1·00
AA 20·66** 20·37* 20·69** 1·00
n-6 20·82** 20·47** 20·87** 0·81** 1·00
A:E 0·70** 0·42** 0·76** 20·77** 20·84** 1·00
GDS 0·23 0·30 0·39* 20·31 20·33 0·34* 1·00
RAV 20·02 20·18 20·17 20·09 0·15 20·12 0·13 1·00
Rcl 0·14 20·02 0·07 20·01 20·09 0·03 0·27 0·39* 1·00
Rec 0·04 20·17 20·13 0·15 0·06 20·26 0·04 0·08 0·28 1·00
BNT 20·19 20·14 20·22 0·15 0·23 20·17 20·20 0·08 20·08 0·08 1·00
Strp 0·17 0·13 0·21 20·16 20·24 0·31 0·19 0·17 0·14 20·12 20·25 1·00
ILF 20·02 0·27 0·22 20·08 20·10 0·07 20·01 0·01 0·26 0·08 20·34* 0·04 1·00
ELF 20·11 0·04 20·03 0·01 0·11 20·16 0·07 0·08 20·09 0·18 20·01 20·01 20·17 1·00
LNS 20·05 20·13 20·14 0·03 0·13 0·02 20·05 0·11 0·17 20·12 0·20 0·20 0·29 20·47** 1·00
TM 0·20 20·10 0·03 20·09 20·04 0·08 20·16 0·07 20·23 20·16 20·10 0·44** 20·27 0·24 20·37* 1·00
DF 20·14 0·16 0·06 0·07 0·11 20·01 20·08 20·03 0·02 20·04 20·3 0·07 0·35* 20·47** 0·25 0·02 1·00
DB 20·19 20·21 20·28 0·17 0·29 20·13 20·40* 0·22 20·24 20·16 0·22 0·25 20·09 20·04 0·07 0·26 0·05 1·00
PF 20·02 0·37* 0·30 20·07 20·11 0·21 0·25 0·19 20·08 20·34* 0·07 0·26 20·03 0·01 20·18 0·23 0·21 20·05 1·00
PH 20·15 0·39* 0·25 20·06 20·01 0·21 0·30 0·21 0·13 20·13 0·11 0·35* 0·16 0·13 20·07 0·19 0·17 0·00 0·66* 1·00
MH 0·24 0·14 0·24 20·37* 20·25 0·50** 0·37* 0·25 0·31 0·09 20·10 0·14 0·22 20·14 20·16 20·10 0·22 20·16 0·15 0·59** 1·00
BP 0·01 0·35* 0·29 20·04 20·10 0·30 0·33* 0·06 0·23 20·24 20·19 0·64** 0·05 0·05 20·20 0·30 0·11 0·03 0·59** 0·85** 0·39* 1·00
Vit 0·06 0·31 0·29 20·23 20·20 0·34* 0·27 0·29 0·29 0·03 20·05 0·11 0·18 20·05 0·03 20·00 0·13 20·09 0·29 0·65** 0·79** 0·49** 1·00
E þ D, EPA þ DHA; AA, arachidonic acid; n-6, total n-6 PUFA; A:E, AA:EPA ratio; GDS, Geriatric Depression Scale; RAV, Rey Auditory Verbal Learning Test, total recall; Rcl, Rey Auditory Verbal Learning Test, delayed recall;
Rec, Rey Auditory Verbal Learning Test, recognition; BNT, Boston Naming Task; Strp, Stroop Colour-Word Test; ILF, Initial Letter Fluency; ELF, Excluded Letter Fluency; LNS, Letter-Number Sequencing; TM, Trail Making;
DF, Digits Forward; DB, Digits Backward; PF, physical functioning; PH, physical health; MH, mental health; BP, bodily pain; Vit, vitality.
*P,0·05, **P,0·01.
† All change variables are calculated so that any change in a positive direction indicates a positive change: i.e. for PUFA, an increase in PUFA levels; for AA:EPA, a decreased ratio; for all other variables, an improvement in the
outcome (e.g. positive change in GDS scores, reduction in depressive symptoms; positive change in bodily pain, reduction in bodily pain, etc.).
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Discussion
We investigated the effects of 6 months’ supplementation with
fish oils rich in either EPA or DHA v. a LA-rich control (safflower
oil) on memory and executive function, depressive symptoms
and health-related quality of life in elderly people with MCI.
A third of the sample had scores that indicated possible
depression, significantly greater than a healthy control group
recruited at baseline(46), and they were equally assigned to
each treatment condition. The treatment was well tolerated
overall, with no adverse effects in the DHA group and a handful
of gastrointestinal complaints in each of the LA and EPA groups.
Depressive symptom scores were significantly reduced after
6 months of high-EPA and high-DHA supplementation com-
pared with LA and increased erythrocyte levels of EPA plus
DHA were associated with improved depressive symptoms,
as was a reduced ratio of AA:EPA. Increased erythrocyte
DHA levels were associated with reduced bodily pain, and,
although not significantly, with other items associated with
physical health. Therefore, reduced depressive symptoms
may to a small degree have been accounted for by reduced
bodily pain resulting from improved physical functioning
with DHA supplementation. Although depressive symptoms
can increase the risk of developing dementia in elderly
people with cognitive impairment, to our knowledge, this
has not been addressed in previous studies.
Research has independently indicated that n-3 PUFA sup-
plementation may assist with both cognitive impairment and
depression, and it is possible that combined depression and
cognitive impairment is indicative of common underlying bio-
logical mechanisms that may in some cases be attributed to
suboptimal n-3 PUFA levels(47). To our knowledge, other
studies have also not yet reported comparisons of high-EPA
and high-DHA supplementation for depressive symptoms or
cognitive impairment. Although high EPA or ethyl-EPA
has been reportedly effective in some studies with
depression(48,49), we cannot rule out the effect of DHA. For
instance, most studies have not correlated increased
erythrocyte PUFA levels with outcomes. In one study that
used a supplement containing DHA plus EPA, significant cor-
relations between increased DHA and improved depressive
symptoms were found(50) (although this study had a large
placebo effect as both groups received counselling, masking
differences between groups)(51). Another study that used a
supplement with an EPA:DHA ratio of 2:1 reported baseline
levels of erythrocyte DHA at 2·4 % and this increased to
5·8 %(52); therefore, it is possible that DHA contributed to the
positive findings. Other methodological considerations
include the fact that one of the pure DHA studies was
also the shortest study on n-3 PUFA and depression (6
weeks)(53). Furthermore, only three studies in depression
have used DHA compared with ten or more that have focused
on EPA(15). The present study indicates that DHA may be
equally, if not more, effective than EPA for improving mood.
This needs to be investigated further in clinical depression.
Given the relative ratios of EPA and DHA in brain tissue,
it may be that EPA is not required, nor effective, in as large
proportions as DHA.
Of the cognitive outcomes, significant improvements were
only detected in the DHA group for Initial Letter Fluency, a
test of fluid thinking ability. Scores on Digits Backward also
showed trends for improvement in the DHA group. These
tests measure executive function, which is impaired in demen-
tia. Increased DHA was correlated with improved Initial Letter
Fluency, although not statistically significant. It should be
noted that our sample had baseline EPA plus DHA levels
over 5 % of erythrocyte fatty acids, whereas Chiu et al.(18)
had an average combined level of 4·2 %. Therefore, it is poss-
ible that our MCI sample had higher levels than those that
have derived cognitive benefits from n-3 PUFA. This may
also be attributed in part to the small sample size, the outcome
measures and/or a lower n-6:n-3 ratio in our population. Our
final numbers in each group were smaller than the numbers in
MCI subgroups from previous studies that detected reduced
cognitive decline with 2 g n-3 PUFA over 6 months(18,19).
There is also variation in an individual’s performance on cog-
nition from day to day, and it is possible, as discussed pre-
viously(15) that the failure of this and many other studies that
employ a range of cognitive tests to measure outcomes is
due to this daily variation being larger than nutritional treat-
ment effects, thereby potentially rendering the tests largely
insensitive to such effects.
In conclusion, these results indicate that DHA-rich and EPA-
rich fish oils may be effective for depressive symptoms and
health parameters, exerting variable effects on cognitive and
physical outcomes. Reducing n-6 PUFA intake as well as
increasing n-3 PUFA intake for a more balanced ratio may
be beneficial, and this should also be explored further. It is
possible that reductions in mood and verbal fluency in the
LA group represented a normal decline in this population,
although we did observe significant correlations between a
decreased ratio of AA:EPA and improved mood. The present
findings suggest that pure EPA supplements employed in
some mental health studies may not be the optimal choice.
Future research should further investigate this in larger, clini-
cally depressed samples of people with MCI and conduct
longitudinal follow-up to assess whether the risk of pro-
gression to dementia is reduced in these populations.
Research with n-3 PUFA and mental health in elderly popu-
lations should also factor in favourable influences of fish oil
on physical function, particularly joint pain, which could
also have an impact on mood.
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